The persistent presence of nitrates in the atmosphere has long been a concern for environmental scientists. Despite efforts to reduce emissions over the past few decades, nitrate levels remain stubbornly high. A recent study published in Nature Communications sheds light on this enigma, revealing that chemical processes within the atmosphere are responsible for the persistence of these pollutants.

The research team led by Hokkaido University’s Professor Yoshinori Iizuka examined nitrate deposition history from 1800 to 2020 in an ice core taken from southeastern Greenland. The results showed a gradual increase in nitrates up to the 1970s, followed by a slower decline after the 1990s. This trend mirrors the changes in emissions of nitrate precursors over the same period.

The study’s findings suggest that factors other than emission reductions are driving the persistence of atmospheric nitrates. The researchers used a global chemical transport model to investigate these factors and discovered that atmospheric acidity is the key culprit. As acidity levels rise, more nitrates become trapped in particulate form, enabling them to persist longer and travel farther.

The implications of this study are significant. Accurate measurements of particulate nitrates in ice cores provide valuable data for refining climate modeling predictions. Moreover, the findings suggest that atmospheric nitrates will soon replace sulfates as the primary aerosol in the Arctic, further amplifying warming in the region.

As Professor Iizuka notes, “Ours is the first study to present accurate information for records of particulate nitrates in ice cores.” The persistence of these pollutants highlights the importance of continued research into atmospheric chemistry and climate modeling. By understanding the complex interactions within our atmosphere, we can better predict and prepare for the challenges that lie ahead.

Ultra-compact lenses have revolutionized the field of optics, enabling the creation of smaller, more efficient, and cost-effective optical devices. These innovative lenses, known as metalenses, are flat, ultra-thin, and lightweight, making them ideal for a wide range of applications, from camera technology to next-generation microscopy tools.

The key to this breakthrough lies in the use of special metasurfaces composed of nanostructures that modify the direction of light. By harnessing the power of nonlinear optics, researchers can now convert infrared light into visible radiation, opening up new possibilities for authentication, security features, and advanced imaging techniques.

Professor Rachel Grange at ETH Zurich has developed a novel process that enables the fabrication of lithium niobate metalenses using chemical synthesis and precision nanoengineering. This innovative technique allows for mass production, cost-effectiveness, and faster fabrication than other methods, making it an exciting development in the field of optics.

The potential applications of ultra-compact lenses are vast, from counterfeit-proof banknotes to advanced microscopy tools that can reveal new details about materials and structures. The use of simple camera detectors to convert infrared light into visible radiation could revolutionize sensing technologies, while reducing equipment needs for deep-UV light patterning in electronics fabrication.

As researchers continue to explore the possibilities offered by ultra-compact lenses, it’s clear that we’ve only scratched the surface of what this technology can achieve. With its potential to transform industries and improve our understanding of the world around us, ultra-compact lenses are an exciting development that promises to unlock new possibilities for light.

SAVANA is a groundbreaking algorithm that uses machine learning to accurately identify structural variants and copy number aberrations in cancer genomes. This innovative tool has been developed to overcome the limitations of existing analysis tools, which often fall short when analyzing long-read sequencing data. The complex structure of cancer genomes means that standard analysis tools can lead to false-positive results and unreliable interpretations of the data.

Researchers at EMBL’s European Bioinformatics Institute (EMBL-EBI) and the R&D laboratory of Genomics England have developed SAVANA in collaboration with clinical partners at University College London (UCL), the Royal National Orthopaedic Hospital (RNOH), Instituto de Medicina Molecular João Lobo Antunes, and Boston Children’s Hospital. The algorithm was tested across 99 human tumour samples and has shown remarkable accuracy in distinguishing between true cancer-related genomic alterations and sequencing artefacts.

“SAVANA changes the game,” said Isidro Cortes-Ciriano, Group Leader at EMBL-EBI. “By training the algorithm directly on long-read sequencing data from cancer samples, we created a new method that can tell the difference between true cancer-related genomic alterations and sequencing artefacts, thereby enabling us to elucidate the mutational processes underlying cancer using long-read sequencing with unprecedented resolution.”

The team’s focus was clear: create a tool sophisticated enough to characterise complex cancer genomes but practical enough for clinical use. SAVANA can accurately distinguish somatic structural variants, copy number aberrations, tumour purity, and ploidy – all key to understanding tumour biology and guiding clinical treatment decisions.

Its rapid analysis and robust error correction make SAVANA well suited for clinical use. The method was recently applied to study osteosarcoma, a rare and aggressive bone cancer that mostly affects young people, where it helped researchers uncover new genomic rearrangements, providing novel insights into how osteosarcoma evolves and progresses.

“The capability to accurately detect structural variants is transformative for clinical diagnostics,” said Adrienne Flanagan, Professor at UCL, Consultant Histopathologist at RNOH. “SAVANA could help us confidently identify genomic alterations relevant for diagnosis and prognosis. Ultimately, this means we would be better placed to deliver personalised treatments for cancer patients.”

The UK is investing significantly in genomic sequencing technologies as part of the NHS Genomic Medicine Service. This initiative aims to improve diagnostic accuracy and support personalised cancer treatments. However, investments in clinical genomics will only achieve their intended impact if genomic data are interpreted accurately.

“Using SAVANA will ensure clinicians receive accurate and reliable genomic data, enabling them to confidently integrate advanced genomic sequencing methods such as long-read sequencing into routine patient care,” said Greg Elgar, Director of Sequencing R&D at Genomics England.

SAVANA is being deployed as part of nationwide initiatives, such as the UK Stratified Medicine Paediatrics project funded by Cancer Research UK and Children With Cancer UK, and co-led by Cortes-Ciriano. This project aims to develop more efficacious and less toxic treatments for childhood cancers using advanced sequencing technologies to better understand tumour biology and monitor disease recurrence.

Additionally, SAVANA is being used in Societal, Ancestry, Molecular and Biological Analyses of Inequalities (SAMBAI), a Cancer Grand Challenges funded project aimed at addressing cancer disparities in recent African heritage populations.